araag2/HINT huggingface dataset:
Clinical trial NCT01257464 (phase 2, status: terminated)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: sitagliptin, placebo
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  19 years of age or older

          -  Cystic fibrosis-related diabetes with or without fasting hyperglycemia either
             untreated or using only pre-prandial repaglinide or pre-prandial bolus insulin therapy

        Exclusion Criteria:

          -  Age under 19 years

          -  Use of basal insulin therapy

          -  Creatinine Clearance < 50 mL/min

          -  Active cystic fibrosis exacerbation

          -  Pregnancy

          -  Women of child-bearing age not using effective contraception

          -  Current or prior use of DPPIV inhibitor
Clinical trial NCT01500200 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: alks 5461, placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with a major depressive episode (MDE)

          -  Body mass index less than or equal to 40 kg/m2

          -  Have been treated with an adequate dose of SSRI/SNRI during the current MDE for at
             least 8 weeks, with the same, adequate dose over the last 4 weeks that is expected to
             remain stable throughout the study

          -  History of inadequate response during the entire current MDE to 1 or 2 adequate
             antidepressant treatments, including current treatment

          -  Be otherwise physically healthy

        Exclusion Criteria:

          -  Have an axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder,
             schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder,
             obsessive-compulsive disorder, panic disorder, acute stress disorder, or posttraumatic
             stress disorder

          -  Have a clinically significant current axis II diagnosis of borderline, antisocial,
             paranoid, schizoid, schizotypal, or histrionic personality disorder

          -  Are experiencing hallucinations, delusions, or any psychotic symptomatology in the
             current MDE

          -  Receive new onset psychotherapy within 6 weeks of screening

          -  Use of opioid agonists (eg, codeine, oxycodone, morphine) within 14 days before
             screening

          -  Have received electroconvulsive therapy during the current MDE

          -  Have attempted suicide within the past 2 years

          -  Have a thyroid pathology

          -  Have a history of a seizure disorder or of neuroleptic malignant syndrome/serotonin
             syndrome

          -  Have a positive test for human immunodeficiency virus (HIV)

        Additional inclusion/exclusion criteria may apply
Clinical trial NCT00191503 (phase 2, status: completed)
Conditions: adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: pemetrexed, gemcitabine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven adenocarcinoma

          -  No obvious primary on routine history, physical examination, and investigations

          -  Patients greater than or equal to 18 years of age

          -  ECOG Performance Status 0-1

          -  Patients requiring opioids for pain control must be on a fixed analgesic regimen aimed
             to provide adequate pain control with no more than 3 breakthrough (supplemental) doses
             of analgesics per day to control pain; Additional inclusion criteria due apply, but
             not are not listed here.

        Exclusion Criteria:

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry

          -  Unable to stabilize pain and analgesics for a period of 7 days prior to starting study
             treatment

          -  Prior treatment with chemotherapy

          -  Bilirubin greater than or equal to 40 mol/L

          -  AST or ALT greater than or equal to 5 times the upper limit of normal (ULN);
             Additional exclusion criteria due apply, but not are not listed here.
Clinical trial NCT00003605 (phase 2, status: withdrawn)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    no patient accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV indolent B-cell lymphoma
        Diffuse small cleaved cell lymphoma Follicular small cleaved cell lymphoma Follicular mixed
        cell lymphoma Follicular large cell lymphoma At least 1 lymph node or visceral lesion at
        least 2 cm in diameter

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Lymphocyte count less than 5,000/mm3 Hepatic: Not specified
        Renal: Not specified Other: No active infection No concurrent life threatening disease Not
        pregnant Effective contraception required of all fertile patients

        PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma
Clinical trial NCT00737633 (phase 2, status: terminated)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: vi-0521
SMILES: CC(C)(N)CC1=CC=CC=C1
Reason stopped: 
    limited regulatory value to uncontrolled trials. no safety/efficacy concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have completed the qualifying DM-230 trial

          -  If females of child-bearing potential, subjects must be using adequate contraception

          -  Provide written informed consent

          -  Be willing and able to comply with scheduled study visits, treatment plan, lab tests
             and other study procedures

          -  Be greater than 80% compliant in study medication use during the last three visits for
             DM-230

        Exclusion Criteria:

          -  Subjects who have developed one or more morbidities during the DM-230 trial that would
             pose a safety concern
Clinical trial NCT01181050 (phase 2, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: nnc0142-0002, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of RA meeting the American College of Rheumatology 1987 (ACR1987)
             criteria, obtained at least three months prior to dosing with the trial product

          -  Subjects with active RA having a Disease Activity Score (DAS28-CRP) of 4.5 or more, at
             least five tender and five swollen joints (can be the same), including one swollen
             wrist or at least two swollen ipsilateral metacarpophalangeal (MCP) joints (second to
             fifth)

          -  Concomitant treatment with methotrexate (MTX) (7.5-25 mg/week) for at least 12 weeks,
             with stable dose for at least 4 weeks prior to dosing

          -  Ability to be examined by Magnetic Resonance Imaging (MRI)

          -  Having failed no biologic therapies for RA and no more than two non-biologic disease
             modifying antirheumatic drugs

        Exclusion Criteria:

          -  Chronic inflammatory autoimmune disease other than RA (rheumatoid arthritis)

          -  Any ongoing chronic or active infectious disease or microbial infection requiring
             systemic oral or intravenous treatment against infection within 1 month prior to trial
             start

          -  Body mass index (BMI) below or equal to 18 or above or equal to 40 kg/m^2
Clinical trial NCT00308750 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, pemetrexed, docetaxel, carboplatin
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  You must have been diagnosed with non-small cell lung cancer.

          -  You must be able to visit the doctor's office weekly during the active treatment
             period and as needed during the study follow-up period.

          -  You must be willing and able to swallow capsules.

          -  Your entry labs and medical tests must meet study requirements.

          -  You must be willing to have blood samples drawn and tissue samples obtained for gene
             and protein testing.

        Exclusion Criteria:

          -  You have received radiation within 2 weeks of study enrollment.

          -  You have previously received any anti-cancer drug therapy for non-small cell lung
             cancer.

          -  You have an active infection or other serious condition.

          -  You take aspirin or aspirin-like medication regularly and are not able to stop taking
             them for a few days during each cycle of chemotherapy.

          -  You have recently lost a significant amount of weight.
Clinical trial NCT00639327 (phase 2/phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: s-1 + irinotecan, irinotecan
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven inoperable advanced gastric adenocarcinoma (including
             adenocarcinoma of the gastroesophageal junction) or relapse gastric adenocarcinoma

          -  Subjects must be able to take orally

          -  Subjects must be confirmed to be PD status by picture diagnosis after first-line
             chemotherapy using S-1 alone, S-1 + Cisplatinum or S-1 + taxane, except S-1 + CPT-11

          -  Within 4 weeks from the diagnosis of PD

          -  Total dosage of S-1 at the first-line is over 2,240mg/m2 in S-1 alone treatment,
             1,680mg/m2 in the S-1 combination

          -  ECOG performance status ≤ 1

          -  Follow up Age 20 or over

          -  Life expectancy estimated more than 12 weeks

          -  Hgb ≥ 8 g/dL, WBC 4,000-12,000/mm3, ANC ≥ 2,000/mm3, platelets ≥ 100,000/mm3

          -  Creatinine ≤ upper normal limit (UNL)

          -  Total bilirubin ≤ 1.5 X UNL

          -  Written informed consent

        Exclusion Criteria:

          -  S-1 + CPT-11 was employed as a first-line

          -  Any other cytotoxic agents therapy, immuno-therapy, radiation-therapy

          -  After S-1 adjuvant

          -  Suspended cases by adverse events by S-1 or S-1 combination

          -  Excessive amounts of ascites require drainage

          -  Known brain metastases

          -  History of hypersensitivity to fluoropyrimidines and CPT-11

          -  Pregnancy or lactation women, or women with suspected pregnancy or men with willing to
             get pregnant

          -  Active double cancer

          -  Gastrointestinal bleeding

          -  Any subject judged by the investigator to be unfit for any reason to participate in
             the study
Clinical trial NCT01685983 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: abiraterone acetate, prednisolone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate (stage IV)

          -  Has documented Prostate Specific Antigen (PSA) progression according to
             protocol-specific prostate specific antigen working group (PSAWG) eligibility criteria

          -  Has undergone prior chemotherapy for prostate cancer with regimen(s) containing
             Docetaxel

          -  Has an ongoing androgen deprivation with serum testosterone less than 50 ng/dL

          -  Has not received radiotherapy, chemotherapy, or immunotherapy at least 30 days prior
             to the treatment

          -  Eastern Cooperative Oncology Group Performance Status less than or equal to 2

        Exclusion Criteria:

          -  Active or uncontrolled autoimmune disease that may require corticosteroid therapy

          -  Serious or uncontrolled co-existent non-malignant disease, including active and
             uncontrolled infection

          -  Uncontrolled hypertension

          -  Hemoglobin less than or equal to 9.0 g/dL independent of transfusion

          -  Has abnormal liver function tests

          -  Surgery or local prostatic intervention within 30 days of the first dose
Clinical trial NCT00109473 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: growth hormone, cortecosteroid
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Age ≥ 5 years.

          -  Diagnosis of Crohn's disease (CD) with ileo-colonic involvement as determined by
             standard clinical, radiological, and pathological criteria.

          -  Moderate to severely active CD as defined by a PCDAI (Pediatric Crohn's Disease
             Activity Index) ≥ 30.

          -  Currently taking Prednisone or Budesonide at starting dose (not tapering)

          -  May continue stable doses of AZA/6-MP, methotrexate, and/or mesalamine at entry.

          -  For the 52 week extension, baseline bone age ≤ 12 years for girls and ≤ 13 years for
             boys.

          -  For the 52 week extension phase, remission or mild Crohn's disease as determined by a
             PCDAI < 30.

        Exclusion Criteria:

          -  Acute critical illness

          -  Active neoplasia

          -  Diabetes mellitus

          -  History of intracranial lesion and/or neoplasia

          -  Severe disease requiring hospitalization for treatment

          -  Current therapy with infliximab as this may independently rapidly reduce clinical
             disease activity and promote mucosal healing

          -  Use of prednisone or budesonide and in tapering phase

          -  Family history of colorectal cancer before age 50

          -  Personal or familial history of familial polyposis syndrome

          -  Pregnancy (positive pregnancy test) prior to randomization

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial other than the
             Pediatric IBD (Inflammatory Bowel Disease) registry
Clinical trial NCT00853229 (phase 2, status: terminated)
Conditions: vulvodynia, vulvar vestibulitis
ICD codes: N94.818, N94.819, N94.810
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Reason stopped: 
    not feasible due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult women age 18 or greater

          -  Vulvodynia as defined as chronic vulvar discomfort or pain, characterized by burning,
             stinging, irritation or rawness of the female genitalia in cases in which there is no
             infection or skin disease of the vulva or vagina causing these symptoms. Pain may be
             constant or intermittent, localized or diffuse. Symptoms may be consistent with either
             Generalized Vulvodynia (diffuse or focal and constant or unremitting symptoms present
             in the labia majora, labia minora, and/or the vestibule that are not necessarily
             caused by touch or pressure to the vulva) or Vulvar Vestibulitis Syndrome (pain only
             in the vestibule and only during or after touch or pressure is applied).

          -  Pain ≥ 40 on 100mm VAS

          -  Practicing reliable form of birth control defined as sterilization, hormonal
             contraception, abstinence, IUD

          -  Must be able to attend follow up visits and are not likely to leave the area during
             the study period

        Exclusion Criteria:

          -  Atrophic vaginitis, active bacterial vaginosis, yeast, and herpetic infections

          -  Current pregnancy diagnosed by positive serum or urine pregnancy test

          -  Current breastfeeding

          -  Seizure disorder or other chronic neurologic disease

          -  Diagnosis of chronic renal insufficiency defined as creatinine >1.4

          -  Unable to read and speak English

          -  Contraindication to pregabalin or history of prior use of pregablin

          -  Chronic narcotic or benzodiazepine use

          -  Chronic alcohol abuse

          -  Other chronic pain disorders, (ie. chronic pelvic pain, endometriosis, interstitial
             cystitis)

          -  Chronic neuropathic pain or anything affecting sensation (ie. MS, stroke)
Clinical trial NCT00141661 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: pf-04494700 - low dose arm, pf-04494700 - high dose arm, placebo comparator
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probably Alzheimer's disease for at least 1 year.

          -  Mini Mental State Exam (MMSE) score between 12-26 at screening.

          -  Participants must be receiving a cholinesterase inhibitor and/or memantine for at
             least 4 months, and on a stable dose for at least 2 months.

        Exclusion Criteria:

          -  Current evidence of a neurological or psychiatric illness that could contribute to
             dementia.

          -  Living alone.

          -  Poorly controlled high blood pressure.
Clinical trial NCT00139360 (phase 2, status: completed)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        LEVEL A (second line): after confirmed progression on standard first line treatment with
        dacarbazine.

        LEVEL B (first line): when objective clinical response is observed in LEVEL A, patients
        will be included for first line treatment with bevacizumab

        Inclusion Criteria:

          -  Histologically confirmed metastatic (unresectable) melanoma and with progressive
             disease

          -  WHO performance status 0-2

          -  Age >18 years

          -  Able to undergo outpatient treatment

          -  Patients must have clinically and/or radiographically documented measurable disease
             according to RECIST criteria

          -  At least 4 weeks since adjuvant interferon alpha

          -  Recovered from prior chemotherapy

          -  Major surgical procedure or significant traumatic injury within 28 days prior to study
             treatment start. Biopsy or fine needle aspiration within 5 days prior to study
             treatment start. Central venous line placement must be inserted at least 5 days prior
             to treatment start.

          -  Minimum required laboratory data:

        Hematology: absolute granulocytes > 1.0 x 109/L platelets > 100 x 109/L Biochemistry:
        bilirubin < 1.5 x upper normal limit serum creatinine within normal limits INR < 1.5

          -  Before patient registration/randomization, written informed consent must be given
             according to national and local regulations.

        Exclusion Criteria:

          -  No pregnant or lactating patients can be included

          -  No prior interferon alpha or IL-2 for metastatic disease

          -  No more than 1 prior chemotherapy regimen for metastatic disease

          -  No clinical evidence of coagulopathy

          -  No brain metastases

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No history of thrombosis

          -  No full-dose oral coumarin-derived anticoagulants (INR>1.5) or heparin, thrombolytic
             agents, or chronic, daily treatment with aspirin (>325 mg/day)

          -  No non-steroidal anti-inflammatory medications (those known to inhibit platelet
             function at doses used to treat chronic inflammatory diseases)

          -  No uncontrolled hypertension

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial